Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells

Wang, Zhipeng; Tan, Jiao; McConville, Christopher; Kannappan, Vinodh; Tawari, Patricia Erebi; Brown, James E.; Ding, Jin; Armesilla, Ángel Luis; Irache, Juan M.; Mei, Qibing; Tan, Yuhuan; Liu, Ying; Jiang, Wen Guo; Bian, Xiu‐Wu; Wang, Weiguang

doi:10.1016/j.nano.2016.08.001

Cited by 81 publications

(58 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epirubicin-adsorbed nanodiamonds displayed high efficacy in inducing the elimination of chemoresistant LCSCs [179] . Poly lacticco-glycolic acid-encapsulated disulfiram strongly inhibits LCSCs and has a synergistic cytotoxicity with 5-FU or sorafenib [180] . Gao et al [181] developed a GPC3-targeted CAR and found that it obviously suppressesed HCC growth.…”

Section: Treatment Targeting Lcscsmentioning

confidence: 99%

Advances in surface markers of liver cancer stem cell

Zhang¹,

Gong²,

Yan³

et al. 2019

View full text Add to dashboard Cite

Liver cancer stem cells (LCSCs), a small subpopulation that constitutes liver cancer heterogeneity, play a vital role in cancer initiation, invasion, recurrence, metastasis, and resistance to chemo-radiotherapy. It is believed that therapies targeting LCSCs can improve the efficacy of conventional chemotherapy and radiotherapy by completely eliminating tumors while preventing recurrence. Therefore, during last decades, numerous surface markers for LCSCs have been identified and characterized in many subtypes of liver cancer, especially in hepatocellular carcinoma (HCC). These well-recognized surface markers significantly promote the therapeutic efficacy that identifies, targets and destroys LCSCs. Meanwhile, there have been intensive studies that aim to investigate the molecular mechanism of how stemness contributes to liver cancer relapse, recurrence and resistance. However, liver cancer stemness seems to be regulated by a hierarchical organization and crosstalk of a wide variety of signaling pathways. Using individual or few LCSC surface markers may not be able to completely reveal the intrinsic stemness hierarchy. From an integrated perspective, understanding of recent advances in LCSC surface markers remains important and urgent. In this review, we concentrate on demonstrating the indispensable roles of LCSC surface markers in identification and characterization of multiple cancer stages including initiation, invasion, metastasis, resistance and highlighting the cutting-edge therapeutic strategies against cancer stem cells in HCC.

show abstract

Section: Treatment Targeting Lcscsmentioning

confidence: 99%

Advances in surface markers of liver cancer stem cell

Zhang¹,

Gong²,

Yan³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Therefore, a drug delivery system which protects DSF from metabolism in the blood stream would expedite its translation into the clinic as a treatment for NSCLC. We recently demonstrated that PLGA nanoparticles can extend the half-life of DSF in blood from under 2 minutes to 7 hours [46]. To further develop our DSF-loaded PLGA nanoparticles it is imperative that we understand how the choice of formulation and sonication time influences the ability of the PLGA nanoparticles to protect the DSF from degradation in the bloodstream.…”

Section: The Ability Of the 10% W/w Dsf-loaded Plga Nanoparticles To mentioning

confidence: 99%

“…The DSF-loaded PLGA nanoparticles in combination with copper significantly inhibited the liver CSC population and demonstrated very promising anticancer efficacy and anti-metastatic effect in a liver cancer mouse model [46].…”

Section: Introductionmentioning

confidence: 97%

Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer

Najlah

Ahmed

Iqbal

et al. 2017

European Journal of Pharmaceutics and Biopharmaceutics

Self Cite

View full text Add to dashboard Cite

Non-Small Cell Lung Cancer (NSCLC) is the most common type of lung cancer in both men and women. A recent phase IIb study demonstrated that disulfiram (DSF) in combination with cisplatin and vinorelbine was well tolerated and prolonged the survival of patients with newly diagnosed NSCLC. However, DSF is rapidly (4 minutes) metabolised in the bloodstream and it is this issue which is limiting its anticancer application in the clinic. We have recently demonstrated that a low dose of DSF-loaded PLGA nanoparticles supplemented with oral Cu inhibited tumour growth and reduced metastasis in a xenograft mouse lung cancer model. Here we demonstrate the influence of PLGA polymer, stabilizer loading and molecular weight as well as sonication time on the characteristics, including DSF release and the cytotoxicity of 10% w/w DSF-loaded PLGA nanoparticles. The paper demonstrates that the choice of PLGA as no significant influence on the characteristics of the nanoparticles apart from their DSF release, which is due to the differing degradation rates of the polymers. However, increasing the loading and molecular weight of the stabilizer as well as the sonication time reduced the size of the nanoparticles, reduced their ability to protect the DSF from reacting with Cu and degrading in serum, while increasing their DSF release rate and cytotoxicity. Additionally, increasing the sonication time resulted in the premature degradation of the PLGA, which increased the permeability of the nanoparticles further decreasing their ability to protect DSF from reacting with Cu and degrading in serum, while increasing their DSF release rate and cytotoxicity.

show abstract

“…Many literatures have reported that PCL or PLGA could be served as compatible biomaterials to build nanocarrier-based delivery systems [38][39][40]. Herein, PCL was utilized to stabilize hydrophobic core, while mPEG-PLGA was used to improve the solubility of nanoparticles owing to pegylation [41][42][43][44][45] (Fig.…”

Section: Preparation and Characterization Of The Nanoformulationsmentioning

confidence: 99%

Curcumin-encapsulated polymeric nanoparticles for metastatic osteosarcoma cells treatment

et al. 2017

View full text Add to dashboard Cite

Osteosarcoma is a high-class malignant bone cancer with a less than 20% five-year survival rate due to its early metastasis potential. There is an urgent need to develop a versatile and innoxious drug to treat metastatic osteosarcoma. Curcumin (Cur) has shown its potential for the treatment of many cancers; however, the clinical implication of native curcumin is severely hindered by its intrinsic property. In this study, a mixed system of monomethoxy (polyethylene glycol)-poly(d, l-lactide-co-glycolide)/poly(ε-caprolactone) (mPEG-PLGA/PCL) was used to build a formulation of curcuminencapsulated nanoparticles (Cur-NPs), which significantly improved the solubility, stability and cellular uptake of curcumin. Moreover, the Cur-NPs were superior to free curcumin in the matter of inhibition on the proliferation, migration and invasion of osteosarcoma 143B cells. It was found that both free curcumin and Cur-NPs could decrease the expressions of c-Myc and MMP7 in the level of mRNA and protein, which explained why free curcumin and Cur-NPs could inhibit the proliferation and invasion of metastatic osteosarcoma 143B cells. The Cur-NPs provided a promising strategy for metastatic osteosarcoma treatment.

show abstract

Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells

Cited by 81 publications

References 50 publications

Advances in surface markers of liver cancer stem cell

Advances in surface markers of liver cancer stem cell

Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer

Curcumin-encapsulated polymeric nanoparticles for metastatic osteosarcoma cells treatment

Contact Info

Product

Resources

About